AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+18.55%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$389M
AUM Growth
+$389M
(+14%)
Cap. Flow
+$10.9M
Cap. Flow
% of AUM
2.8%
Top 10 Holdings %
Top 10 Hldgs %
87.23%
Holding
44
New
10
Increased
9
Reduced
7
Closed
9
Top Buys
| 1 |
Insmed
INSM
|
$43.7M |
| 2 |
argenx
ARGX
|
$36.9M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$36.5M |
| 4 |
Trevi Therapeutics
TRVI
|
$7.18M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$5.6M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$50M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$29M |
| 3 |
Protagonist Therapeutics
PTGX
|
$17.2M |
| 4 |
Arcellx
ACLX
|
$15M |
| 5 |
Merus
MRUS
|
$6.73M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.18B
| $87.4M | 21.03% |
924,204
+385,716
| +72% | +$36.5M |
|
|
2
Insmed
INSM
$30.9B
| $75.8M | 18.23% |
752,712
+434,473
| +137% | +$43.7M |
|
|
3
argenx
ARGX
$43.2B
| $43.2M | 10.39% |
78,311
+67,000
| +592% | +$36.9M |
|
4
Soleno Therapeutics
SLNO
$3.57B
| $41.4M | 9.97% |
494,424
-4,049
| -0.8% | -$339K |
|
|
5
Eli Lilly
LLY
$660B
| $23.9M | 5.76% |
30,700
-64,187
| -68% | -$50M |
|
6
Boston Scientific
BSX
$158B
| $16.7M | 4.01% |
155,200
+25,500
| +20% | +$2.74M |
|
|
7
Merus
MRUS
$5.05B
| $15.6M | 3.76% |
296,750
-127,890
| -30% | -$6.73M |
|
8
Quest Diagnostics
DGX
$20B
| $14.7M | 3.53% |
81,717
+25,000
| +44% | +$4.49M |
|
9
AstraZeneca
AZN
$248B
| $13.3M | 3.21% |
190,752
| – | – |
|
|
10
Trevi Therapeutics
TRVI
$887M
| $7.18M | 1.73% |
+1,311,840
| New | +$7.18M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.7B
| $6.84M | 1.65% |
20,970
-7,630
| -27% | -$2.49M |
|
|
12
Regeneron Pharmaceuticals
REGN
$61.2B
| $5.6M | 1.35% |
+10,671
| New | +$5.6M |
|
13
Scholar Rock
SRRK
$3.22B
| $4.47M | 1.08% |
126,285
-45,900
| -27% | -$1.63M |
|
14
Revolution Medicines
RVMD
$7.4B
| $3.83M | 0.92% |
104,190
| – | – |
|
|
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
| $3M | 0.72% |
63,930
+10,000
| +19% | +$470K |
|
16
EyePoint Pharmaceuticals
EYPT
$820M
| $2.98M | 0.72% |
316,700
| – | – |
|
17
AbbVie
ABBV
$374B
| $2.69M | 0.65% |
+14,500
| New | +$2.69M |
|
18
Viking Therapeutics
VKTX
$3.09B
| $2.56M | 0.62% |
96,479
+6,200
| +7% | +$164K |
|
19
Ascendis Pharma
ASND
$12.1B
| $2.11M | 0.51% |
12,240
+4,800
| +65% | +$828K |
|
20
TG Therapeutics
TGTX
$4.73B
| $1.96M | 0.47% |
54,515
| – | – |
|
21
Vertex Pharmaceuticals
VRTX
$103B
| $1.96M | 0.47% |
+4,400
| New | +$1.96M |
|
22
Ultragenyx Pharmaceutical
RARE
$3.1B
| $1.52M | 0.37% |
+41,830
| New | +$1.52M |
|
23
United Therapeutics
UTHR
$18.5B
| $1.44M | 0.35% |
5,000
| – | – |
|
|
MREO
24
Mereo BioPharma
MREO
$280M
| $1.29M | 0.31% |
475,361
+54,002
| +13% | +$146K |
|
|
25
Protagonist Therapeutics
PTGX
$3.68B
| $1.27M | 0.31% |
22,951
-310,900
| -93% | -$17.2M |
|